Skip to content

Chronic Cough and Small Fiber Neuropathy

Chronic Cough and Small Fiber Neuropathy

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03787511
Acronym
CHROCOS
Enrollment
7
Registered
2018-12-26
Start date
2022-06-14
Completion date
2022-12-31
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Cough, Type 2 Diabetes

Keywords

cough, diabetes, small fiber neuropathy

Brief summary

Diabetic patients with and without chronic cough will be included in this study. After giving their informed consent, the patients will perform a spirometry, chest X-ray at the inclusion visit. Cough will be assessed using the cough visual analog scale (VAS) and the Leicester Cough Questionnaire (LCQ). Within 60 days, the patient will perform neurophysiological tests. The neurophysiological assessment will be concluded with a skin biopsy to evaluate small fiber neuropathy. The aim of the study is to compare the proportion of small fiber neuropathy between diabetic patients with chronic cough and those without chronic cough.

Detailed description

Chronic cough is a very common entity that affects 9.6% people worldwide. Given the high number of patients with refractory cough, the concept of cough hypersensitivity syndrome (CHS) has emerged. In CHS, afferent sensory nerves may exhibit a modification of activation patterns with facilitation of encoding signals in response to irritating stimuli. Similar patterns with neuropathic pain have been described. Small fiber neuropathy has never been assessed in chronic cough. Interestingly, diabetic patients experienced cough more frequently than healthy subject. We hypothesized that small fiber neuropathy may explain chronic cough is more frequent in diabetic patients. Within 60 days after inclusion, diabetic patients with and without chronic cough will perform neurophysiological tests such as electromyography, thermotest, QSART (Quantitative Sudomotor Axon Reflex Test and Sudoscan), cardio-vascular tests to study the autonomic nervous system. No risks are expecting with these non-invasive tests. A skin biopsy to evaluate small fiber neuropathy will also be performed.After the neurophysiological tests, a consultation will be scheduled at 6 months. A cough VAS and LCQ will be used to assess cough.

Interventions

OTHERCough assessment

Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough

OTHERNeurological tests and cardiovascular tests

Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough

OTHERSkin biopsy

Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

In diabetic patients with chronic cough: * Chronic cough defined by cough for more than 8 weeks. * Normal chest X-ray * history of type 2 diabetes * Age of diabetes onset\> 40 years * Affiliated or beneficiary person of social security * Free, informed and written consent In diabetic patients without chronic cough * History of type 2 diabetes * Age of discovery of diabetes\> 40 years * Affiliated or beneficiary person of social security * Free, informed and written consent

Exclusion criteria

* Presence of physical signs of peripheral neuropathy * Active smoking or smoking cessation within the last 12 months * Pregnant or lactating woman * History of non-type 2 diabetes (type I, secondary diabetes, monogenic ...) * Cancer within the last 5 years (except cutaneous squamous cell carcinoma) * History of anti-cancer chemotherapy * Suspicion of autoimmune pathology * Active neurological pathology * Electromyography in favor of large fiber neuropathy * Chronic pathology that may interfere with the neurophysiological assessment * Patient who were given anticoagulation drug therapy, anti-cholinergic drugs, beta-blocker and impossibility to withdraw the treatment before neurophysiological tests In diabetic patients without chronic cough, another non-inclusion criteria is acute or chronic cough

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with small fiber neuropathy6 month after inclusion visitThe primary endpoint is the proportion of patients with small fiber neuropathy between diabetic patients with chronic cough and those without chronic cough (defined by at least 2 abnormal neurophysiological tests).

Secondary

MeasureTime frameDescription
proportion of patients with abnormal results of the thermotest6 month after inclusion visitestimate the proportion of patients with abnormal results of the thermotest in each arm (with and without chronic cough)
proportion of patients with pathological results of the sudori-motor response6 month after inclusion visitestimate the proportion of patients with pathological results of the sudori-motor response in each arm (with and without chronic cough)
the proportion of patients with abnormal results of cardiovascular tests6 month after inclusion visitestimate the proportion of patients with abnormal results of cardiovascular tests assessing the autonomic nervous system in in each arm (with and without chronic cough)
proportion of patients with abnormal results of laser evoked potentials6 month after inclusion visitestimate the proportion of patients with abnormal results of laser evoked potentials in each arm (with and without chronic cough)
proportion of patients with abnormal findings of cutaneous biopsy6 month after inclusion visitestimate the proportion of patients with abnormal findings of cutaneous biopsy in in each arm (with and without chronic cough)
values of Leicester Cough Questionnaire (LCQ) in diabetic patients6 month after inclusion visitestimate the values of Leicester Cough Questionnaire in diabetic patients with and without chronic cough. The Leicester Cough Questionnaire comprises 19 items and takes 5 to 10 minutes to complete. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) are calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) is also calculated by adding the domain scores together. Higher scores indicate better quality of life.
values of the DN4 questionnaire in diabetic patients6 month after inclusion visitestimate the values of the DN4 questionnaire in diabetic patients with and without chronic cough. It allows to estimate the probability of neuropathic pain in a patient, through 4 questions divided into 10 check items. The practitioner questions or examines the patient and completes the questionnaire himself. He notes a response ("yes", "no") to each item. At the end of the questionnaire, he counts the answers and assigns the note 1 for each "yes", and the score 0 for each "no". The sum obtained gives the score of the patient, scored out of 10.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORLaurent Guilleminault, MD

University Hospital, Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 2, 2026